DOCSLIB.ORG

2302 Index Prefixes Such As Α-, Β-, O-, M-, P-, D-, L-, N-, O-, R-, S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2302 Index Index Prefixes such as a-, b-, o-, m-, p-, d-, l-, N-, O-, R-, S- and numbers are generally ignored in this alphabetical listing. A Acipen V 1614 Advantage 1051 Aciphex 1826 advantame 45 A2 220 acitretin 30 Advicor 1186, 1473 AA3 976 ackee 1032 Advil 1038 4-AA 689 Aclasta 2279 Adzenys 114 AAtack 2075 aclidinium bromide 31 aelaterin 520 AAtrex 170 Aclovir 40 Aeris 2067 abacavir 1 acne drugs (see anti-acne drugs) Aerobec 196 abamectin 2, 1098 Acnisal 1890 AeroBid 870 Abarax 213 Acomplia 1858 Aerolate 2060 Abba 2 aconite 32 aerosol propellants (see propellants) AB-CHMINACA 1980 aconitine 32 Aerospan 870 ABDF 270 acrivastine 34 afatinib 46 Abelcet 117 acrodynia 1256, 1257, 2066 Afinitor 824 AB-FUBINACA 1980 acrolein 34, 535, 1044 aflatoxin B1 47 Abilify 147 acrylamide 36 Afos 1219 abiraterone acetate 3 acrylfentanyl 37 Afrin 1576 Abitat 147 acrylic amide 36 Agelan 1058 abobotulinumtoxinA 255 acrylonitrile 38 Agenerase 119 abortifacients 325, 1398,1410, 1615 acryloylfentanyl 37 Agent Orange 622, 679, 2149 AB-PINACA 1980 actein 587 Aggrastat 2097 Abraxane 1584 Actidex 599 Aggrenox 688 abrin 4 Acticide 1327 Agilect 1836 absinthe 2076 Actifed 2171 Agit 650 Abstral 844 actinomycin D 39 agomelatine 49 ABT-494 2301 actinospectacin 1941 Agrastat 2097 acamprosate 5 Actiq 844 Agritox 1328 Acapodene 2120 Actimax 1433 AH-7921 50 acarbose 5 Activon 1005 Aimpart 1871 acaricides 102, 403, 431, 791, 2039 Actol 1487 Airbron 22 Acarin 631 Actonel 1860 Airduo 897, 1891 Accolate 519, 2263 Actos 1696 Airtal 8 Accomplia 1858 Actril 1072 Airum 842 Accrufer 1078 Acular 1112 ajmaline 51 Accupril 1820 Acupan 1464 Akatinol 1237 Accuprin 1820 Acuphase 2287 AKB-48 1980 Accuretic 1820 Acuvel 167 akee 1032 Accutane 1091 acyclovir 40, 2194 Akineton 236 Accutrim 1671 Adaferin 42 Akynzeo 1470, 1588 Acebron 9 Adalat 1485 ALA 1128 acebutolol 6 adalimumab 41 alachlor 52 acecainide 1752 Adalin 348 Alanex 52 aceclofenac 8 adapalene 42 AlaQuin 468 Acecor 6 Adapin 712 Alavert 1180 ACE inhibitors 199, 581, 742, 914, 1169, 1634, Adartrel 1871 albendazole 53 1820, 1831, 2127, 2276 Adasept 2153 albiglutide 54 Ace K 12 ADB-CHMINACA 1979 Albistat 1392 Acemox 18 ADB-FUBINACA 1980 albuterol 54 Acenac 8 ADB-PINACA 1980 alcohol 784 acenocoumarol 9 Adcirca 1991 alcohol aversion therapy agents 135, 318, 693 acenocoumarin 9 Adco-Linctopent 267, 1544 alcuronium 56 Aceon 1634 Adderall 114 Aldactazide 1941 acephate 10 Addyi 859 Aldactide 1941 acepromazine 11 Adecut 581 Aldactone 1941 acesulfame 12 adefovir dipivoxil 43 Aldafil 711 Acetadote 22 ademine 2139 aldicarb 57 acetaldehyde 13, 318, 671, 784, 789, 1267, Adempas 1859 Aldifen 677 1504, 1594, 2076 adenine riboside 44 Aldoclor 1332 acetamide 666 Adenocard 44 Aldomet 1332 acetaminophen 14, 131, 1641, 1643 adenosine 44, 634 Aldoril 1332 acetamiprid 17 ADH 2211 aldrin 58 acetanilide 131 Adhansia 1364 Alecensa 60 acetazolamide 18 ADHD drugs (see attention deficit disorder alectinib 60 acetic acid 784, 796 drugs) alendronate 60 acetone 19, 24, 1086, 1352, 1768 Adiazine 1960 alendronic acid 60 acetonitrile 20 Adion 127 Alerion 519 acetophenetidin 1640 Adipex 1662 Aleve 1457 N-acetyl-p-aminophenol 14, 1643 Adipokinetix 1516 Alfacide 1574 acetylcarnitine 21 Adiza 1046 Alfenta 61 6-acetylcodeine 995 Adizem 632 alfentanil 61 acetylcysteine 22 Adlyxin 1172 Alfospas 2097 acetylene 24 adrafinil 45, 1420 Alfusin 62 acetylfentanyl 25 adrenaline 755 alfuzosin 62 acetylmethadol 26 Adriacin 715 Alganex 2022 6-acetylmorphine 994 Adriamycin 715 alimemazine 2162 N-acetylprocainamide 1752 Adronat 60 Alimta 1609 acetylpromazine 11 adulterants 97, 241, 261, 497, 561, 604, 859, alindapril 581 acetylsalicylic acid 27 1139, 1230, 1658, 1666, 1823, 1917, 1919 Alinia 1496 Achromycin 2037 Advagraf 1989 aliskiren 63 aciclovir 40 Advair 897, 1891 alitretinoin 64 Aciforin 909 Advancor 1479 alizapride 65 Acinal 1446 Index 2303 alkaloids 32, 51, 142, 171, 222, 278, 283, 315, amifostine 86 Anamycin 773 363, 364, 509, 549, 739, 768, 930, 941, amikacin 87 Anandron 1490 955, 988, 989, 1004, 1007, 1010, 1031, Amikin 87 Anaprox 1457 1035, 1194, 1197, 1261, 1348, 1357, 1397, amiloride 88 AnaSed 2257 1414, 1428, 1481, 1520, 1536, 1575, 1593, amineptine 89 anasterone 1577, 1683, 1688, 1821, 1823, 1841, 1893, 1901, amino acids 90, 145, 458, 514, 963, 968, 1028, anastrozole 125 1934, 1950, 2002, 2047, 2058, 2059, 2122, 1032, 1036, 1135, 1548, 1895, 2001, 2057, Anavar 1559 2179, 2221, 2226, 2227, 2229, 2261 2178, 2185 Anbesol 1656 Alka-Seltzer 717 1-aminoadamantane 81 Ancef 367 Alkeran 1236 p-aminoaniline 1667 Ancobon 865 alkylating agents 200, 294, 354, 395, 535, 552, 4-aminoantipyrine 689 Ancotil 865 779, 1044, 1220, 1236, 2073, 2172 aminocaproic acid 90, 328 andarine 126 Allegra 851 2-amino-N-ethyl-1-phenylbutane 797 andexanet alfa 137 Allerest 1454 aminoglutethimide 91 Andexxa 137 Allergen 136 aminoglycosides 87, 141, 947, 1102, 1467, Andolex 217 Allergodil 178 1603, 1715, 1947, 2101, 2207 Andriol 2030 allethrin 66 6-aminohexanoic acid 90 Andro 2030 Alleviate 66 7-aminonitrazepam 1498 Androderm 2030 Alli 1546 aminophenazone 95 Androgel 2030 Alloferin 56 p-aminophenol 131, 1503, 1643 androgen receptor antagonists 233, 545, 751, Allopur 67 2-amino-1-phenylbutane 638 895, 1490 allopurinol 67 1-amino-2-phenylpropane 1363 androgen receptor modulators 126, 233, 748, all-trans-retinoic acid 64, 2137 aminophylline 2060 1158 allylbarbital 298 5-(2-aminopropyl)benzofuran 92, 798, 1321 Android 1373 allylbarbitone 298 6-(2-aminopropyl)benzofuran 93 androstanediol 2032 allyl trichloride 2150 5-(2-aminopropyl)indole 93 Androstat 6 1514 Almogran 68 4-aminopyridine 94 androstenedione 127, 578, 1744 almonds 120, 523 aminopyrine 95 androstenetrione 128 Almotrex 68 aminorex 97, 1139, 1321 androsterone 578, 2031 almotriptan 68 p-aminosalicylic acid 98, 188, 1208 Androxy 886 alogliptin 69 5-aminosalicylic acid 188, 1260, 1535, 1964 Anectine 1954 alosetron 70 aminosidine 1603 anesthesia-inducing agents 600, 737, 816, Aloxi 1588 aminosultopride 101 844, 871, 1105, 1299, 1393, 1644, 1774, Alpha Brain 1010, 2234 aminotriazole 106 1839, 2065, 2069, 2085, 2147, 2292 Alphagan 258 amiodarone 99 anesthetic gases and liquids 412, 588, 746, Alphakil 394 amisulpride 101 789, 986, 1082, 1315, 1510, 1916, 2255 alpha-methyldopa 1332 Amitiza 1191 Anethaine 2034 alpha-methylfentanyl 1352 amitraz 102 Anexate 868, 1227 alpha-methyltryptamine 1375 amitriptyline 103 Anexsia 1015 alphaprodine 71 amitrole 106 Angeliq 720 alprazolam 72 Amizol 106 Anginal 688 alprenolol 74 Amloc 107 angiotensin-converting enzyme inhibitors (see alprostadil 75 amlodipine 107 ACE inhibitors) Altace 1831 Ammo 543 angiotensin II receptor antagonists 322, 765, Altoprev 1186 ammonium bromide 267 853, 1076, 1185, 2012, 2204 aluminum 76 ammonium dichromate 438 anidulafungin 129 aluminum phosphide 1682 ammonium molybdate 1423 anileridine 130 Alunbrig 257 ammonium vanadyl tartrate 2206 aniline 131, 1503, 1643 Alupent 1268, 1544 amnesic shellfish poisoning 702 animal poisons 283, 356, 442, 1005, 1900, Alurate 141 amobarbital 108 2052 Aluvia 1178 amodiaquine 110 anions 267, 397, 873, 1501, 1635, 1681 Alventa 2216 Amonate 156 aniracetam 132 alverine 78 amoxapine 111, 1188 anorectic agents (see appetite suppressants) Alvesco 440 amoxicillin 113 Anorex 638 alvimopan 79 Amoxil 113 Anoro Ellipta 2188, 2223 Alzheimer's drugs (see also nootropic agents) amoxycillin 113 Anplag 1899 21, 456, 704, 930, 1010, 1042, 1221, 1237, AMP2 1354 Anquil 204 1383, 1683, 1866, 1988, 2227 Ampamet 132 Ansaid 893 AM-2201 1980 amphetamine 114, 215, 471, 667, 798, 830, Antabuse 693 AM-6527 1980 835, 843, 1168, 1227, 1264, 1277, 1280, antacids 76, 777, 829, 1201, 1512, 1539, 1591, amadacycline 1537 1905 1726, 1826, 1833, 1931 Amanita 80, 1036, 1166, 1436, 1921 l-amphetamine 114, 1280 Antagonil 1474, 2261 amanitin 80 Amphotec 117 Antara 839 amantadine 81 amphotericin B 117 antazoline 133 Amaryl 958, 1270 ampicillin 118 anthelmintic agents 2, 53, 484, 621, 636, 702, Amasulin 358 Ampicin 118 1098, 1139, 1216, 1383, 1432, 1496, 1559, Amatine 1396 Ampiclox 488 1737, 1797, 1976, 2091, 2144, 2151 amatoxin 80 amprenavir 119, 911 Anthex 1216 AMB-FUBINACA 1980 Ampyra 94 anti-acne drugs, 42, 1091, 1890, 1896 Ambien 2280 amrinone 1056 anti-aging drugs 521, 669, 704, 1042, 1463, AmBisome 117 Amrix 528 1568, 1685, 1733 ambrisentan 83 AMT 1375 anti-alcoholism drugs 5, 186, 318, 693, 1448, Ambrosan 83 amudane 977 1451, 2116 ambroxol 83, 267 amygdalin 120 anti-alopecia drugs (see antibaldness drugs) Ambush 1636 amyl nitrite 122, 1501 anti-anginal drugs (see also vasodilators) 122, Amcill 118 amylobarbitone 108 652, 688, 1093, 1096, 1479, 1485, 1506, Amerge 1459 Amytal 108 1618, 1632, 1744, 1834, 2090, 2163, 2219 Americaine 213 anabasine 123 anti-anxiety agents (see also barbiturates, amethocaine 2034 Anabol 1452 benzodiazepines) 72, 293, 348, 352, 406, amethopterin 1301 anabolic steroids 127, 248, 249, 484, 558, 886, 407, 422, 1030, 1249, 1998, 2047, 2197 Ametriex 84 951, 1266, 1281, 1288, 1293, 1373, 1452, anti-arrhythmic agents 44, 51, 99, 133, 287, ametryn 84, 1514, 1559, 1577, 1943, 2030, 2135 439, 603, 652, 692, 699, 719, 857, 1040, amfepramone 638 anabolicum 1158 1074, 1122, 1155, 1201, 1331, 1387, 1485, amfetamine 114 Anadrol 1577 1569, 1689, 1728, 1752, 1766, 1780, 1821, Amias 322 Anafranil 475 2161, 2219 Amicar 90 anagliptin 124 anti-arthritis agents (see also antirheumatic Amidate 816 Anagregal 2084 agents, corticosteroids, COX-2 inhibitors, amidopyrine 95 anagrelide 124 narcotic analgesics, NSAIDs) 41, 139, Amidrin 2260 Analeptin 1978 177, 2102 amifampridine 85 Analginum
Recommended publications
  • Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study

    Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study

    International Journal of Environmental Research and Public Health Article Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study Hsin-Chien Chen 1,* , Chih-Hung Wang 1,2 , Wu-Chien Chien 3,4 , Chi-Hsiang Chung 3,4, Cheng-Ping Shih 1, Yi-Chun Lin 1,2, I-Hsun Li 5,6, Yuan-Yung Lin 1,2 and Chao-Yin Kuo 1 1 Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; [email protected] (C.-H.W.); [email protected] (C.-P.S.); [email protected] (Y.-C.L.); [email protected] (Y.-Y.L.); [email protected] (C.-Y.K.) 2 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan 3 School of Public Health, National Defense Medical Center, Taipei 114, Taiwan; [email protected] (W.-C.C.); [email protected] (C.-H.C.) 4 Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan 5 Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; [email protected] 6 School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan * Correspondence: [email protected]; Tel.: +886-2-8792-7192; Fax: +886-2-8792-7193 Received: 31 July 2020; Accepted: 28 August 2020; Published: 31 August 2020 Abstract: The effect of dextromethorphan (DXM) use in sensorineural hearing loss (SNHL) has not been fully examined. We conducted an animal model and nationwide retrospective matched-cohort study to explore the association between DXM use and SNHL.
  • Minnesota Statutes 1979 Supplement

    Minnesota Statutes 1979 Supplement

    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
  • A Review of Synthetic Fentanyl Metabolism and the Metabolism of Select Synthetic Fentanyl Analogues

    A Review of Synthetic Fentanyl Metabolism and the Metabolism of Select Synthetic Fentanyl Analogues

    A review of synthetic fentanyl metabolism and the metabolism of select synthetic fentanyl analogues Gerard Lee A thesis submitted for the completion of a degree in Master of Forensic Science (Professional Practice) in The School of Veterinary and Life Sciences Murdoch University Supervisors: Associate Professor James Speers (Murdoch) Associate Professor Bob Mead (Murdoch) Semester 1, 2019 i Declaration I declare that this thesis does not contain any material submitted previously for the award of any other degree or diploma at any university or other tertiary institution. Furthermore, to the best of my knowledge, it does not contain any material previously published or written by another individual, except where due reference has been made in the text. Finally, I declare that all reported experimentations performed in this research were carried out by myself, except that any contribution by others, with whom I have worked is explicitly acknowledged. ii Acknowledgements I would like to thank my supervisor Bob Mead for his time guiding me and providing feedback on this endeavour. He has been a great help providing insights and advice from when I started university at Murdoch until now for which I am extremely grateful. To James Speers, thank you for helping me find a direction for this project when I started out. And finally, to my family and friends for their encouragement and support. iii Table of Contents Title page. ...............................................................................................................................I
  • 18 December 2020 – to Date)

    18 December 2020 – to Date)

    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
  • Educational Commentary – Testing for Amphetamines and Related Compounds

    Educational Commentary – Testing for Amphetamines and Related Compounds

    EDUCATIONAL COMMENTARY – TESTING FOR AMPHETAMINES AND RELATED COMPOUNDS Learning Outcomes Upon completion of this exercise, participants will be able to: • list amphetamine-like compounds that may be detected by immunoassay screening tests for amphetamines. • describe the 3 types of amphetamine immunoassays based on their antibody specificity. • discuss common causes of false-positive results when testing for amphetamines. Correct interpretation of testing results for amphetamines and related compounds is dependent on many factors including an understanding of the nomenclature, structure, and metabolism of these compounds. The class of phenethylamine compounds having varying degrees of sympathomimetic activity include amphetamine, methamphetamine, and many other compounds known by several names including amphetamines (as a group), designer drugs often grouped together as ecstasy [3,4- methylenedioxymethamphetamine (MDMA); 3,4-methylenedioxyamphetamine (MDA), and 3,4- methylenedioxy-N-ethylamphetamine (MDEA)], and sympathomimetic amines including ephedrine, pseudoephedrine, and phenylpropanolamine found in over-the-counter (OTC) medications. Amphetamine, a primary amine, and methamphetamine, a secondary amine, have a stereogenic center and have enantiomers or optical isomers designated d (or +) for dextrorotatory and l (or -) for levorotatory. In general, the d isomers are the more physiologically active compounds, but pharmaceutical preparations may consist of either isomer or a mixture of both isomers. When the mixture contains equal concentrations of the 2 enantiomers, it is known as a racemic mixture. The existence of enantiomers for amphetamines creates analytical and interpretative problems. Immunoassay Screening The primary screening methods for detecting amphetamines are immunoassays. The structural similarity to amphetamine or methamphetamine of the compounds previously mentioned makes it difficult to produce antibodies specific for amphetamine, methamphetamine, or both.
  • Treatment Protocol Copyright © 2018 Kostoff Et Al

    Treatment Protocol Copyright © 2018 Kostoff Et Al

    Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al PREVENTION AND REVERSAL OF ALZHEIMER'S DISEASE: TREATMENT PROTOCOL by Ronald N. Kostoffa, Alan L. Porterb, Henry. A. Buchtelc (a) Research Affiliate, School of Public Policy, Georgia Institute of Technology, USA (b) Professor Emeritus, School of Public Policy, Georgia Institute of Technology, USA (c) Associate Professor, Department of Psychiatry, University of Michigan, USA KEYWORDS Alzheimer's Disease; Dementia; Text Mining; Literature-Based Discovery; Information Technology; Treatments Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al CITATION TO MONOGRAPH Kostoff RN, Porter AL, Buchtel HA. Prevention and reversal of Alzheimer's disease: treatment protocol. Georgia Institute of Technology. 2018. PDF. https://smartech.gatech.edu/handle/1853/59311 COPYRIGHT AND CREATIVE COMMONS LICENSE COPYRIGHT Copyright © 2018 by Ronald N. Kostoff, Alan L. Porter, Henry A. Buchtel Printed in the United States of America; First Printing, 2018 CREATIVE COMMONS LICENSE This work can be copied and redistributed in any medium or format provided that credit is given to the original author. For more details on the CC BY license, see: http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License<http://creativecommons.org/licenses/by/4.0/>. DISCLAIMERS The views in this monograph are solely those of the authors, and do not represent the views of the Georgia Institute of Technology or the University of Michigan. This monograph is not intended as a substitute for the medical advice of physicians. The reader should regularly consult a physician in matters relating to his/her health and particularly with respect to any symptoms that may require diagnosis or medical attention.
  • Mixed Antagonistic Effects of the Ginkgolides at Recombinant Human R1 GABAC Receptors

    Mixed Antagonistic Effects of the Ginkgolides at Recombinant Human R1 GABAC Receptors

    Neuropharmacology 63 (2012) 1127e1139 Contents lists available at SciVerse ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Mixed antagonistic effects of the ginkgolides at recombinant human r1 GABAC receptors Shelley H. Huang a, Trevor M. Lewis b, Sarah C.R. Lummis c, Andrew J. Thompson c, Mary Chebib d, Graham A.R. Johnston a, Rujee K. Duke a,* a Discipline of Pharmacology, School of Medical Sciences, Faculty of Medicine, University of Sydney, Australia b School of Medical Sciences, University of New South Wales, Australia c Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom d Faculty of Pharmacy, University of Sydney, Australia article info abstract Article history: The diterpene lactones of Ginkgo biloba, ginkgolides A, B and C are antagonists at a range of Cys-loop Received 11 July 2011 receptors. This study examined the effects of the ginkgolides at recombinant human r1 GABAC recep- Received in revised form tors expressed in Xenopus oocytes using two-electrode voltage clamp. The ginkgolides were moderately 18 June 2012 potent antagonists with IC sinthemM range. At 10 mM, 30 mM and 100 mM, the ginkgolides caused Accepted 24 June 2012 50 rightward shifts of GABA doseeresponse curves and reduced maximal GABA responses, characteristic of noncompetitive antagonists, while the potencies showed a clear dependence on GABA concentration, Keywords: indicating apparent competitive antagonism. This suggests that the ginkgolides exert a mixed-type Ginkgolide Bilobalide antagonism at the r1 GABAC receptors. The ginkgolides did not exhibit any obvious use-dependent Mixed-antagonism inhibition. Fitting of the data to a number of kinetic schemes suggests an allosteric inhibition as Use-dependent a possible mechanism of action of the ginkgolides which accounts for their inhibition of the responses GABAr receptor without channel block or use-dependent inhibition.
  • Drug Formulary Medi-Cal/Healthy Families Drug Formulary • 2014

    Drug Formulary Medi-Cal/Healthy Families Drug Formulary • 2014

    2014 Drug Formulary Medi-Cal/Healthy Families Drug Formulary • 2014 Medi-Cal/Healthy Families Drug Formulary • 2014 TABLE OF CONTENTS MOLINA HEALTHCARE MEDI-CAL/HEALTHY FAMILIES DRUG FORMULARY ....................................................................................4 PRESCRIPTION CLAIMS PROCESSOR .........................................................5 USING THE MOLINA MEDI-CAL/HEALTHY FAMILIES DRUG FORMULARY ....................................................................................6 CLINICAL CONSIDERATIONS .........................................................................6 INDIVIDUAL PRESCRIPTIONS ........................................................................6 GENERIC MEDICATIONS .................................................................................7 PRIOR AUTHORIZATION REQUEST PROCEDURE ......................................7 STEP THERAPY PROCEDURE .......................................................................7 PRESCRIPTION QUANTITY .............................................................................7 URGENT AND AFTER-HOURS MEDICATION POLICY ..................................8 TELEPHONE PRESCRIPTIONS.......................................................................8 DRUG FORMULARY .........................................................................................9 Chapter 1 ANALGESICS ..............................................................................9 Chapter 2 ANTIDIABETIC AGENTS ..........................................................12 Chapter
  • Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry

    Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry

    molecules Article Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry Dasom Shin, Hui-Seung Kang *, Hyungsoo Kim and Guiim Moon New Hazardous Substances Division, Department of Food Safety Evaluation, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong, Cheongju 28159, Korea; [email protected] (D.S.); [email protected] (H.K.); [email protected] (G.M.) * Correspondence: [email protected] Received: 11 August 2020; Accepted: 17 September 2020; Published: 24 September 2020 Abstract: In this work, liquid chromatography–tandem mass spectrometry (LC-MS/MS) method was developed and validated for screening and confirmation of 64 illicit compounds in dietary supplements. The target compounds were illegally used pharmaceutical drugs, prohibited compounds, and not authorized ingredients for different therapeutics (sexual enhancement, weight loss, muscular strengthening, and relaxing products). The validation procedure was performed to evaluate selectivity, linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, and precision according to the Association of Official Analytical Chemists guidelines. The linearity was >0.98 in the range of 1 1 0.5–200 µg L− . The LOQs were in the range 1–10 µg kg− for all target compounds. The accuracy (expressed as recovery) was 78.5–114%. The precision (expressed as the relative standard deviation) was below 9.15%. The developed method was applied for the determination of illicit compounds in dietary supplements collected from websites. As a result, the total detection rate was 13.5% (27 samples detected in 200 samples). The concentrations of detected samples ranged from 0.51 1 to 226 mg g− .
  • Réglementation De La Pharmacie

    Réglementation De La Pharmacie

    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
  • Seminar on Drug Chirality

    Seminar on Drug Chirality

    Drug chirality: Stereoselectivity in the action and disposition of anaesthetic agents Isomerism Isomers: Drugs with the same chemical composition and molecular formula. Isomers Structural Stereoisomers isomers •Constitutional / Structural isomerism: Same molecular formula but different chemical structure as the arrangement of atoms is different. Stereoisomerism: Same molecular formula and chemical structure but a different configuration (i.e. different three dimensional spatial arrangement of their atoms) Two types: 1. Optical isomers 2. Geometrical isomers Optical isomerism Enantiomers: A pair of stereoisomers that are non-superimposable mirror images of each other. Cause of enantiomerism: presence of a chiral centre. Physiochemical properties ( solubility, melting and boiling points, ionization constant) are identical. Separation is difficult. Diastereomers: Stereoisomers that are not mirror images of each other and are not enantiomeric. Physiochemical properties are different. Separation is easy. What is chirality? Chiral - derived from a Greek word chiros, meaning handedness. A molecule or object that is not superimposable on its mirror image is said to be chiral. Chiral centre / asymmetric carbon / stereogenic centre – A carbon atom attached to four different substituents. • Achiral molecules usually contain a plane of symmetry but chiral molecules do not. • A plane of symmetry is a mirror plane that cuts the molecule in half, so that one half of the molecule is a reflection of the other half. • With chiral compounds, the plane of the polarized light is rotated through an angle . A compound that rotates polarized light is said to be optically active. •With achiral compounds, the light that passes through the compound remains unchanged. A compound that does not change the plane of polarized light is said to be optically inactive.
  • Changing Pattern of Epidemic Dropsy in North India

    Changing Pattern of Epidemic Dropsy in North India

    Epidemic Dropsy in North India N. Sharma et al. ORIGINAL ARTICLE Changing Pattern of Epidemic Dropsy in North India NAVNEET SHARMA1,*, NAINA MOHAN 2, ASHISH BHALLA1, AMAN SHARMA1, SURJIT SINGH 1 1 The Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India 2 King's College London, Strand, London, United Kingdom Abstract Background: Epidemic dropsy occurs due to ingestion of mustard oil contaminated with oil from Argemone mexicana, leading to edema and tenderness of the abdomen, upper and lower limbs. In this study, clinical profiles of patients presented with epidemic dropsy in north India are described. Methods: This was a prospective study of patients presented with epidemic dropsy to the emergency department of Nehru Hospital, during the period from March 2004 to December 2011. Inclusion criteria were patients presenting with tender bilateral pitting leg edema and dermal telangiectasia. Clinical and laboratory data of patients were entered into case record forms at the time of presentation until discharge from the hospital. Results: Leg edema was the principal symptom in our series, and was in concurrence with current literature. Erythema has only been reported in 35-82% of published series, though it was present in all of our patients. Similarly, features such as diarrhea, hepatomegaly and anemia were more frequent in our cases compared to the literature. Furthermore, pancytopenia which was documented on peripheral blood counts in 54% of our cases has never been reported before. Conclusion: Epidemic dropsy should be considered in patients presenting with progressive erythema, edema, and tenderness of the limbs who had a history of consumption of mustard oil and confirmation of Argemone oil contamination according to laboratory tests.